List of Publications

Original Articles

Number of Citations according to Google Scholar: 4559 (As of February 15, 2016)

Reports of original investigations in refereed journals.


Edwards K, Goodman W. Improvement of neuropsychological function in cognitively impaired multiple sclerosis treated with natalizumab. *Int. J MS Care* 2012; 14:100-104

Edwards K, Goodman WA. Natalizumab Use for Neuropsychological Deficits in Relapsing Multiple Sclerosis (P04. 116) *Neurology* 2012; Meeting Abstracts 1: P7.218


Teter B, Apatoff B, Coyle P, Edwards K et all. Capture of Patient-Perceived Negative Mood Traits to Improve Treatment for Patients with Multiple Sclerosis. *Neurology* 2011; 76: A71-A71


42. Edwards K, DePalma T, Rosenthal B. Chronic cluster and associated hemifacial spasm of fifteen years duration relieved with botulinum toxin type A. *Headache* 2008; 48:S51-S51

51. Edwards K, Royall D, Hershey L et. al, Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study *Dementia and Geriatric Cognitive Disorders* 2007; 23 (6): 401-405
54. Edwards K. Rivastigmine reduces need for neuropsychotherapeutics in AD *InPharma* 2005; 1504: 10
58. Sadowsky C, Edwards K, Etemad B et al Maintaining effective treatment in dementia: A case series on patients switched to rivastigmin *Primary Care Psychiatry* 2004:9:71-75


74. Edwards K, O'Connor JT. Switching from donepezil or rivastigmine to galantamine in clinical practice. *International Psychogeriatrics* 2003; 15:253-254


115. K Edwards, A Block, B Richardson, D Potter A community hospital experience with aptiganel hydrochloride for acute ischemic stroke on hospital utilization outcome Journal of Stroke and Cerebrovascular Diseases 1997; 6 (6), 460


In press or in preparation

1. Fox E, Edwards K, Burch JG, Wynn D et al Outcomes of Switching Directly to Oral Fingolimod from Injectable Therapies: Results of the Evaluate Patient OutComes (EPOC) Study in Relapsing Multiple Sclerosis. *In Press Mult Sclerosis and Related Disorders*

2. Cree B, Edwards K, Crayton H, Kantor D, et al. Change from baseline in PROs (TSQM, FSS, BDI-II) and CGI-I in previously treated Interferon and glatiramer patients switching to Gilenya vs staying on interferons or glatiramer. *In preparation*